<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><front><journal-meta><journal-id journal-id-type="nlm-ta">Thromb Res</journal-id><journal-id journal-id-type="iso-abbrev">Thromb. Res</journal-id><journal-title-group><journal-title>Thrombosis Research</journal-title></journal-title-group><issn pub-type="ppub">0049-3848</issn><issn pub-type="epub">1879-2472</issn><publisher><publisher-name>The Authors. Published by Elsevier Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7301826</article-id><article-id pub-id-type="publisher-id">S0049-3848(20)30269-3</article-id><article-id pub-id-type="doi">10.1016/j.thromres.2020.06.027</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Is COVID-19 associated thrombosis caused by overactivation of the complement cascade? A literature review</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0005"><name><surname>Fletcher-Sandersj&#x000f6;&#x000f6;</surname><given-names>Alexander</given-names></name><email>alexander.fletcher-sandersjoo@ki.se</email><xref rid="af0005" ref-type="aff">a</xref><xref rid="af0010" ref-type="aff">b</xref><xref rid="cr0005" ref-type="corresp">&#x0204e;</xref></contrib><contrib contrib-type="author" id="au0010"><name><surname>Bellander</surname><given-names>Bo-Michael</given-names></name><xref rid="af0005" ref-type="aff">a</xref><xref rid="af0010" ref-type="aff">b</xref></contrib><aff id="af0005"><label>a</label>Department of Neurosurgery, Karolinska University Hospital, Stockholm, Sweden</aff><aff id="af0010"><label>b</label>Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden</aff></contrib-group><author-notes><corresp id="cr0005"><label>&#x0204e;</label>Corresponding author at: Department of Neurosurgery, Karolinska University Hospital, Elite Hotel Carolina, 4th floor, 171 76 Stockholm, Sweden. <email>alexander.fletcher-sandersjoo@ki.se</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>18</day><month>6</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><month>10</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>18</day><month>6</month><year>2020</year></pub-date><volume>194</volume><fpage>36</fpage><lpage>41</lpage><history><date date-type="received"><day>23</day><month>4</month><year>2020</year></date><date date-type="rev-recd"><day>10</day><month>6</month><year>2020</year></date><date date-type="accepted"><day>16</day><month>6</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 The Authors</copyright-statement><copyright-year>2020</copyright-year><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract id="ab0005"><p>Severe acute respiratory syndrome coronavirus 2 is responsible for the current COVID-19 pandemic resulting in an escalating number of cases and fatalities worldwide. Preliminary evidence from these patients, as well as past coronavirus epidemics, indicates that those infected suffer from disproportionate complement activation as well as excessive coagulation, leading to thrombotic complications and poor outcome. In non-coronavirus cohorts, evidence has accumulated of an interaction between the complement and coagulation systems, with one amplifying activation of the other. A pressing question is therefore if COVID-19 associated thrombosis could be caused by overactivation of the complement cascade? In this review, we summarize the literature on thrombotic complications in COVID-19, complement activation in coronavirus infections, and the crosstalk between the complement and coagulation systems. We demonstrate how the complement system is able to activate the coagulation cascade and platelets, inhibit fibrinolysis and stimulate endothelial cells. We also describe how these interactions see clinical relevance in several disorders where overactive complement results in a prothrombotic clinical presentation, and how it could be clinically relevant in COVID-19.</p></abstract><abstract abstract-type="author-highlights" id="ab0010"><title>Highlights</title><p><list list-type="simple" id="l0005"><list-item id="li0005"><label>&#x02022;</label><p id="p0005">SARS-CoV-2 is responsible for the current COVID-19 pandemic.</p></list-item><list-item id="li0010"><label>&#x02022;</label><p id="p0010">COVID-19 organ deterioration may be attributed to complement system overactivation.</p></list-item><list-item id="li0015"><label>&#x02022;</label><p id="p0015">COVID-19 patients suffer from thrombotic complications.</p></list-item><list-item id="li0020"><label>&#x02022;</label><p id="p0020">There is a prothrombotic interaction between complement and coagulation.</p></list-item><list-item id="li0025"><label>&#x02022;</label><p id="p0025">It is yet unknown if this interaction explains the thrombotic complications in COVID-19.</p></list-item></list></p></abstract><kwd-group id="ks0005"><title>Keywords</title><kwd>COVID-19</kwd><kwd>Coronavirus</kwd><kwd>Coagulation</kwd><kwd>Thrombosis</kwd><kwd>Complement</kwd><kwd>Inflammation</kwd><kwd>Thromboembolism</kwd></kwd-group></article-meta></front><body><sec id="s0005"><label>1</label><title>Introduction</title><p id="p0030">Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus (<xref rid="dt0025" ref-type="term">CoV</xref>) responsible for the current COVID-19 pandemic. The deterioration of organ function following infection from the disease has largely been attributed to a maladaptive immune response [<xref rid="bb0005" ref-type="bibr">1</xref>], of which the complement system is an integral part [<xref rid="bb0010" ref-type="bibr">2</xref>]. In addition to complement activation, COVID-19 patients also suffer from excessive coagulation, leading to thrombotic complications and poor clinical outcome [<xref rid="bb0015" ref-type="bibr">3</xref>]. In non-CoV cohorts, there is evidence of interactions between the complement and coagulation systems, resulting in an amplification of their otherwise targeted responses [<xref rid="bb0020" ref-type="bibr">4</xref>,<xref rid="bb0025" ref-type="bibr">5</xref>,<xref rid="bb0070" ref-type="bibr">[14]</xref>, <xref rid="bb0075" ref-type="bibr">[15]</xref>, <xref rid="bb0080" ref-type="bibr">[16]</xref>, <xref rid="bb0085" ref-type="bibr">[17]</xref>, <xref rid="bb0090" ref-type="bibr">[18]</xref>, <xref rid="bb0095" ref-type="bibr">[19]</xref>, <xref rid="bb0100" ref-type="bibr">[20]</xref>, <xref rid="bb0105" ref-type="bibr">[21]</xref>, <xref rid="bb0110" ref-type="bibr">[22]</xref>, <xref rid="bb0115" ref-type="bibr">[23]</xref>,<xref rid="bb0030" ref-type="bibr">6</xref>,<xref rid="bb0120" ref-type="bibr">[24]</xref>, <xref rid="bb0125" ref-type="bibr">[25]</xref>, <xref rid="bb0130" ref-type="bibr">[26]</xref>, <xref rid="bb0135" ref-type="bibr">[27]</xref>, <xref rid="bb0140" ref-type="bibr">[28]</xref>, <xref rid="bb0145" ref-type="bibr">[29]</xref>, <xref rid="bb0150" ref-type="bibr">[30]</xref>,<xref rid="bb0035" ref-type="bibr">[7]</xref>, <xref rid="bb0040" ref-type="bibr">[8]</xref>, <xref rid="bb0045" ref-type="bibr">[9]</xref>, <xref rid="bb0050" ref-type="bibr">[10]</xref>, <xref rid="bb0055" ref-type="bibr">[11]</xref>, <xref rid="bb0060" ref-type="bibr">[12]</xref>, <xref rid="bb0065" ref-type="bibr">[13]</xref>]. However, it is not known whether this process occurs and could explain the thrombotic complications in COVID-19. In this review, we summarize the literature on thrombotic complications in COVID-19, complement activation in CoV infections, and the crosstalk between the complement and coagulation system.</p></sec><sec id="s0010"><label>2</label><title>The complement system</title><p id="p0035">The complement system is part of the innate immune response [<xref rid="bb0155" ref-type="bibr">31</xref>,<xref rid="bb0160" ref-type="bibr">32</xref>] and made up of serine proteases that share the same ancestral genes as coagulation proteins [<xref rid="bb0165" ref-type="bibr">33</xref>]. Much like the coagulation system, its activation involves the interaction of plasma and membrane-bound proteins. The function of the complement system is carried out by opsonization, generating pro-inflammatory mediators, and activating the membrane attack complex (<xref rid="dt0055" ref-type="term">MAC</xref>, also known as the terminal complement complex C5b-9) [<xref rid="bb0170" ref-type="bibr">34</xref>]. This activation generally follows three pathways, each triggered by different agents, which converge in the formation of C3 convertase. C3 convertase then cleaves C3 into C3b, a potent opsonin, and C3a, an anaphylatoxin [<xref rid="bb0170" ref-type="bibr">34</xref>]. Further propagation of C3b also results in the generation of C5 convertase, which cleaves C5 to C5a and C5b. C5b forms a complex with other complement proteins that make up the C5b-9 membrane attack complex (MAC). Deposition of MAC on cell membranes leads to calcium influx and cell lysis, but can also activate intracellular signaling at lower doses [<xref rid="bb0170" ref-type="bibr">34</xref>]. The complement system is also regulated by complement control proteins, including C1-inhibitor (CI-INH), decay-accelerating factor (<xref rid="dt0035" ref-type="term">DAF</xref>), C4-binding protein (<xref rid="dt0020" ref-type="term">C4BP</xref>), factor H and other [<xref rid="bb0170" ref-type="bibr">34</xref>,<xref rid="bb0175" ref-type="bibr">35</xref>].</p></sec><sec id="s0015"><label>3</label><title>Complement-mediated thrombosis</title><sec id="s0020"><label>3.1</label><title>Complement and the coagulation cascade</title><p id="p0040">One of the principal driving forces behind the coagulation cascade is the exposure to tissue factor, which initiates the intrinsic coagulation pathway. C5a has been shown to increase tissue factor activity in both circulating form [<xref rid="bb0020" ref-type="bibr">4</xref>] and on endothelial cells [<xref rid="bb0025" ref-type="bibr">5</xref>]. This is supported by ex-vivo studies that have showed that inhibition of C3 or C5 leads to reduced expression of tissue factor [<xref rid="bb0030" ref-type="bibr">6</xref>,<xref rid="bb0035" ref-type="bibr">7</xref>]. The same reaction can be seen on mast cells, where the complement system is able to induce the expression of tissue factor and promote a prothrombotic phenotype [<xref rid="bb0040" ref-type="bibr">8</xref>]. Other studies have also shown that MASP-1 and MASP-2, a group of serine proteases that initiate the lectin complement pathway, can cleave prothrombin to form activated thrombin [<xref rid="bb0045" ref-type="bibr">9</xref>], and autonomously activate fibrinogen and factor XIII (fibrin stabilizing factor) [<xref rid="bb0050" ref-type="bibr">10</xref>,<xref rid="bb0055" ref-type="bibr">11</xref>]. MASP-1 knockout mice show significantly longer tail-bleeding times compared to controls, highlighting the possible clinical significance of these results [<xref rid="bb0180" ref-type="bibr">36</xref>]. Complement system inhibitors are also able to inhibit the coagulation cascade [<xref rid="bb0060" ref-type="bibr">12</xref>,<xref rid="bb0065" ref-type="bibr">13</xref>]. C1 esterase inhibitor (<xref rid="dt0015" ref-type="term">C1-INH</xref>) can inhibit factor XII [<xref rid="bb0070" ref-type="bibr">14</xref>] and thrombin [<xref rid="bb0075" ref-type="bibr">15</xref>], and C4b-binding protein (C4BP) has been shown to inhibit protein S, a co-factor for the activated protein-C pathway of coagulation inhibition. Thus, the complement system is capable of activating the coagulation cascade (<xref rid="t0005" ref-type="table">Table 1</xref>
, <xref rid="f0005" ref-type="fig">Fig. 1</xref>
).<table-wrap position="float" id="t0005"><label>Table 1</label><caption><p>Complement-mediated coagulopathy: molecular interactions.</p></caption><alt-text id="al0010">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Complement substrate</th><th>Effect on hemostasis</th></tr></thead><tbody><tr><td>C3a</td><td>Platelet activation</td></tr><tr><td>C5a</td><td>Increased tissue factor activity<break/>Increased expression of endothelial P-selectin<break/>Increased expression of PAI-1 on mast cells</td></tr><tr><td>MAC (C5b-9)</td><td>Platelet activation<break/>Increased binding of coagulation factors Va and Xa<break/>Increased release of factor V from platelet alpha-granules<break/>Induces endothelial cells to secrete von Willebrand factor</td></tr><tr><td>MASP 1</td><td>Activates thrombin<break/>Activates TAFI<break/>Activates factor XII<break/>Activates fibrinogen</td></tr><tr><td>MASP 2</td><td>Activates thrombin</td></tr><tr><td>C1-INH</td><td>Inhibits factor XII<break/>Inhibits thrombin<break/>Inhibits plasmin</td></tr><tr><td>C4BP</td><td>Inhibits protein S</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: C&#x0202f;=&#x0202f;complement factor; MAC&#x0202f;=&#x0202f;membrane attack complex; MASP&#x0202f;=&#x0202f;mannan-binding lectin serine protease; C1-INH&#x0202f;=&#x0202f;C1 esterase inhibitor; C4BP&#x0202f;=&#x0202f;C4b-binding protein; PAI-1&#x0202f;=&#x0202f;plasminogen activator inhibitor-1; TAFI&#x0202f;=&#x0202f;thrombin-activatable fibrinolysis inhibitor.</p></fn></table-wrap-foot></table-wrap><fig id="f0005"><label>Fig. 1</label><caption><p>Schematic overview of complement-mediated coagulopathy.</p></caption><alt-text id="al0005">Fig. 1</alt-text><graphic xlink:href="gr1_lrg"/></fig></p></sec><sec id="s0025"><label>3.2</label><title>Complement and platelets</title><p id="p0045">Early murine studies showed that C3- and C5 deficient mice have prolonged tail-bleeding times and reduced platelet function [<xref rid="bb0080" ref-type="bibr">16</xref>], lending support to the notion that complement activates platelets. More recent studies have highlighted how MAC is able to activate platelets and enhance platelet aggregation [<xref rid="bb0085" ref-type="bibr">[17]</xref>, <xref rid="bb0090" ref-type="bibr">[18]</xref>, <xref rid="bb0095" ref-type="bibr">[19]</xref>], and that C3 deficiency in mice reduces thrombus incidence, fibrin deposition and platelet activation [<xref rid="bb0100" ref-type="bibr">20</xref>]. The assembly of MAC on human platelets has also been shown to result in a dose-dependent increase in the binding of coagulation factors Va and Xa, which increases platelet prothrombinase activity and initiates the release of the prothrombotic factor V from alpha-granules [<xref rid="bb0105" ref-type="bibr">21</xref>,<xref rid="bb0110" ref-type="bibr">22</xref>]. Moreover, removal of external Ca<sup>2+</sup> from this reaction seems to inhibit the MAC-initiated release of the platelet alpha-granule storage pool, suggesting that the effects that lead to increased platelet prothrombinase activity are mediated by influx of Ca<sup>2+</sup> across the MAC pore [<xref rid="bb0110" ref-type="bibr">22</xref>]. Other studies have further demonstrated that platelets have receptors for C3a that can mediate their activation [<xref rid="bb0185" ref-type="bibr">37</xref>]. Thus, both C3 and the MAC of the complement system appear capable of activating platelets. This has seen clinical relevance in trauma patients, where complement activation has been shown to increased platelet aggregation [<xref rid="bb0115" ref-type="bibr">23</xref>,<xref rid="bb0120" ref-type="bibr">24</xref>]. In summary, evidence points to a relationship between complement and platelets on multiple levels that can result in disproportionate platelet activation, as well the release of platelet-derived microparticles that further stimulates this reaction (<xref rid="t0005" ref-type="table">Table 1</xref>, <xref rid="f0005" ref-type="fig">Fig. 1</xref>).</p></sec><sec id="s0030"><label>3.3</label><title>Complement and fibrinolysis</title><p id="p0050">Fibrinolysis is the enzymatic breakdown of fibrin in blood clots. In a study by Brown et al., C1-INH in its native state was found to inhibit plasmin [<xref rid="bb0135" ref-type="bibr">27</xref>], which could lead to decreased fibrinolysis and increased thrombus formation. Similarly, complement factors have been shown to stimulate the expression of plasminogen activator inhibitor-1 (<xref rid="dt0070" ref-type="term">PAI-1</xref>) by mast cells, further inhibiting fibrinolysis and thereby presumably promoting thrombosis [<xref rid="bb0040" ref-type="bibr">8</xref>]. In vitro-studies have also showed that MASP-1 is able to activate thrombin-activated fibrinolytic inhibitor (<xref rid="dt0095" ref-type="term">TAFI</xref>), an inhibitor of fibrinolysis [<xref rid="bb0050" ref-type="bibr">10</xref>,<xref rid="bb0055" ref-type="bibr">11</xref>]. Thus, evidence shows that fibrinolysis can be regulated by both complement factors and complement inhibitors, through limitation of the formation of plasminogen to plasmin and stimulating endogenous fibrinolysis inhibitors, respectively (<xref rid="t0005" ref-type="table">Table 1</xref>, <xref rid="f0005" ref-type="fig">Fig. 1</xref>). In addition to this, factors of fibrinolysis are able to modify complement activity as well. Probably the most important finding is that plasmin can activate C3 and C5 independently of C3 convertase [<xref rid="bb0190" ref-type="bibr">[38]</xref>, <xref rid="bb0195" ref-type="bibr">[39]</xref>, <xref rid="bb0200" ref-type="bibr">[40]</xref>, <xref rid="bb0205" ref-type="bibr">[41]</xref>], yielding functional MAC. This means that plasmin bridges thrombosis and the immune response by liberating C5a and inducing MAC assembly [<xref rid="bb0210" ref-type="bibr">42</xref>]. Plasmin, therefore, in addition to thrombin, also seems to be a key C5a generating enzyme.</p></sec><sec id="s0035"><label>3.4</label><title>Complement and endothelial activation</title><p id="p0055">Evidence supports the hypothesis that the endothelium is a key target organ of COVID-19 [<xref rid="bb0215" ref-type="bibr">43</xref>]. This is of interest as studies have shown that complement factors can stimulate endothelial activation. Probably the most important finding in this context is that MAC is able to induce endothelial cells to secrete von Willebrand factor [<xref rid="bb0140" ref-type="bibr">28</xref>], which seems to be accompanied by an increase in prothrombinase activity. While the precise mechanism behind this remains unclear, the assembly of MAC on endothelial cell membranes appears to result in an influx of Ca<sup>2+</sup> across the plasma membrane, which in turn leads to an increase in endothelial cytosolic Ca<sup>2+</sup> and secretion of platelet adhesive von Willebrand factor [<xref rid="bb0140" ref-type="bibr">28</xref>]. This capacity of MAC to induce exposure of prothrombinase enzyme complex may contribute to fibrin deposition associated with immune endothelial injury [<xref rid="bb0145" ref-type="bibr">29</xref>]. C5a has also been found to induce a dose-dependent expression of endothelial P-selectin similar to that of thrombin [<xref rid="bb0150" ref-type="bibr">30</xref>]. This is important for the recruitment and aggregation of platelets to areas of vascular injury through platelet-fibrin and platelet-platelet binding. Thus, the complement system can also induce thrombosis by inducing endothelial cells to release von Willebrand factor and express P-selectin (<xref rid="t0005" ref-type="table">Table 1</xref>, <xref rid="f0005" ref-type="fig">Fig. 1</xref>).</p></sec><sec id="s0040"><label>3.5</label><title>Clinical examples of complement-mediated thrombosis</title><p id="p0060">Clinically relevant interplay between the complement and coagulation system is seen in several disorders (&#x0201c;complementopathies&#x0201d;) where complement overactivation results in a prothrombotic state. Paroxysmal nocturnal hemoglobinuria (<xref rid="dt0080" ref-type="term">PNH</xref>) is a hematological disorder associated with an acquired deficiency in the synthesis of glycophosphatidylinositol that renders erythrocytes susceptible to complement-mediated destruction [<xref rid="bb0220" ref-type="bibr">44</xref>]. PNH is also associated with an increased risk of thrombosis linked to complement-mediated platelet activation [<xref rid="bb0225" ref-type="bibr">45</xref>]. Atypical hemolytic uremic syndrome (<xref rid="dt0005" ref-type="term">aHUS</xref>) is another rare disease caused by excessive activation of the complement system, due to production of anti-factor H autoantibodies or genetic mutations in complement regulatory proteins, that results in platelet activation and thrombotic microangiopathy [<xref rid="bb0230" ref-type="bibr">46</xref>]. Moreover, complement deposition on platelets has been linked to the severity and infarct volume in acute stroke [<xref rid="bb0235" ref-type="bibr">47</xref>]. Increased complement deposition on platelets is also seen in systemic lupus erythematosus (<xref rid="dt0090" ref-type="term">SLE</xref>) patients with a history of venous thromboembolism [<xref rid="bb0240" ref-type="bibr">48</xref>]. Together, these disorders demonstrate that increased complement activity leads to thrombotic events.</p><p id="p0065">Eculizumab has been a therapeutic revolution for patients with aHUS and PNH. The agent, an anti-C5 antibody that blocks formation of MAC and C5a generation, has been shown to reduce thromboembolic events in patients with PNH [<xref rid="bb0245" ref-type="bibr">49</xref>] and aHUS [<xref rid="bb0250" ref-type="bibr">50</xref>]. It has also shown clinical benefit in treating thrombotic microangiopathy secondary to sepsis-induced <xref rid="dt0040" ref-type="term">DIC</xref> [<xref rid="bb0255" ref-type="bibr">51</xref>], as well as provide potential benefits in antiphospholipid syndrome [<xref rid="bb0180" ref-type="bibr">36</xref>].</p></sec></sec><sec id="s0045"><label>4</label><title>Thrombosis and hypercoagulability in COVID-19</title><p id="p0070">Growing evidence from multiple studies indicates that COVID-19 patients suffer from excessive coagulation, leading to increased thrombosis and poor clinical outcome [<xref rid="bb0015" ref-type="bibr">3</xref>]. In particular, the incidence of venous thromboembolism (<xref rid="dt0105" ref-type="term">VTE</xref>) among COVID-19 patients in intensive care units (<xref rid="dt0050" ref-type="term">ICU</xref>) appears to be higher compared to those reported in other ICU-cohorts [<xref rid="bb0260" ref-type="bibr">52</xref>]. In an early study from Wuhan, 25% of hospitalized COVID-19 patients developed VTE [<xref rid="bb0265" ref-type="bibr">53</xref>]. A similar incidence of 31% was reported in a later European study of 184 patients with severe COVID-19 [<xref rid="bb0270" ref-type="bibr">54</xref>]. A third study noted increased VTE in COVID-19 patients with <xref rid="dt0010" ref-type="term">ARDS</xref> compared with a matched historic non-CoV ARDS cohort [<xref rid="bb0275" ref-type="bibr">55</xref>]. In addition, the largest COVID-19 autopsy study to date found pulmonary embolism (<xref rid="dt0075" ref-type="term">PE</xref>) in 21% of the patients and deep vein thrombosis (<xref rid="dt0045" ref-type="term">DVT</xref>) in 40% [<xref rid="bb0280" ref-type="bibr">56</xref>]. In addition to VTE, ischemic stroke has been recognized as a complication to severe COVID-19 [<xref rid="bb0285" ref-type="bibr">57</xref>]. In a current preprint study of 2132 patients, COVID-19 was found to be independently associated with an increased risk of stroke compared to a matched Influenza group [<xref rid="bb0290" ref-type="bibr">58</xref>]. A recent pooled analysis of 11,685 COVID-19 patients also found that 20% had a documented myocardial injury [<xref rid="bb0295" ref-type="bibr">59</xref>].</p><p id="p0075">From a laboratory standpoint, blood hypercoagulability is frequently encountered in COVID-19 patients [<xref rid="bb0300" ref-type="bibr">60</xref>,<xref rid="bb0305" ref-type="bibr">61</xref>]. D-dimer has gained particular attention as a predictor of poor outcome, with several studies concluding that increased D-dimer values correlate to injury severity and death [<xref rid="bb0305" ref-type="bibr">[61]</xref>, <xref rid="bb0310" ref-type="bibr">[62]</xref>, <xref rid="bb0315" ref-type="bibr">[63]</xref>, <xref rid="bb0320" ref-type="bibr">[64]</xref>, <xref rid="bb0325" ref-type="bibr">[65]</xref>, <xref rid="bb0330" ref-type="bibr">[66]</xref>, <xref rid="bb0335" ref-type="bibr">[67]</xref>, <xref rid="bb0340" ref-type="bibr">[68]</xref>]. D-dimer levels also seem to gradually increase during the diseases course [<xref rid="bb0305" ref-type="bibr">61</xref>]. Pooled results from a recent meta-analysis also revealed that prothrombin time and D-dimer levels were significantly higher in patients with severe compared to those with mild COVID-19 [<xref rid="bb0345" ref-type="bibr">69</xref>]. Similar results have been reported for activated partial thromboplastin time [<xref rid="bb0015" ref-type="bibr">3</xref>]. In an Italian study of 22 patients admitted to the ICU due to COVID-19 associated respiratory failure, cases also showed markedly hypercoagulable thromboelastometry profiles, as reflected by shorter Clot Formation Time (CFT) in and higher Maximum Clot Firmness (MCF), indicative of hypercoagulability rather than consumptive coagulopathy [<xref rid="bb0340" ref-type="bibr">68</xref>].</p></sec><sec id="s0050"><label>5</label><title>Complement activation in coronavirus infections</title><p id="p0080">In a rodent study of SARS-CoV, which is closely related to SARS-CoV-2, Gralinski and colleagues reported increased complement activity and found that C3-deficient mice exhibited less respiratory dysfunction (despite equivalent viral loads in the lung), fewer neutrophils and inflammatory monocytes, and reduced lung pathology and lower cytokine and chemokine levels in both the lungs and sera compared to controls [<xref rid="bb0350" ref-type="bibr">70</xref>]. This showed that the complement system is an important host mediator of SARS-CoV-induced disease and that complement activation regulates a systemic proinflammatory response to SARS-CoV infection. In another rodent model of MERS-CoV, increased concentrations of C5a and C5b-9 were found in sera and lung tissues, and blockade of the C5a-C5aR axis lead to the decreased tissue damage, as manifested by reduced apoptosis and T cell regeneration in the spleen [<xref rid="bb0355" ref-type="bibr">71</xref>]. This highlighted the fact that excessive complement activation contributed to the dysregulated host immune responses that contribute to the severe outcome of MERS-CoV infection as well. While these studies suggest that complement activation regulates a systemic inflammatory response to CoV pneumonia, data on the role of complement activation in the development of specifically SARS-CoV-2 have been scarce. However, in recent paper that examined skin and lung tissues from 5 patients with severe COVID-19 characterized by respiratory failure (n&#x0202f;=&#x0202f;5) and purpuric skin rash (n&#x0202f;=&#x0202f;3), significant deposits of C5b-9, C4d, and (MASP)-2 were found in the microvasculature of lung tissue, consistent with systemic activation of the alternative and lectin-based complement pathways. The purpuric skin lesion samples showed a similar deposition of C5b-9 and C4d [<xref rid="bb0360" ref-type="bibr">72</xref>]. This means that at least a subset of sustained, severe COVID-19 may be accompanied by activation of complement pathways and an associated procoagulant state. Further supporting these findings, a recent preprint reported that N proteins of SARS-CoV, MERS-CoV and SARS-CoV-2 were found to bind to MASP-2, resulting in aberrant complement activation and aggravated inflammatory lung injury. Complement hyper-activation was also detected, and a suppressive effect was observed when two deteriorating COVID-19 patients were treated with an anti-C5a monoclonal antibody [<xref rid="bb0365" ref-type="bibr">73</xref>]. Another preprint measured erythrocyte-bound C3b, iC3b, C3dg and C4d using flow cytometry in patients. Here, the amount of erythrocytes with bound complement activation products was markedly elevated in hospitalized COVID-19 patients compared to with healthy donors, and continued to increase during the first 7&#x0202f;days. Moreover, COVID-19 erythrocytes bound viral spike protein, suggesting activation of the classic pathway of complement and immune complex deposition on the erythrocytes [<xref rid="bb0370" ref-type="bibr">74</xref>]. Thus, preliminary evidence from COVID-19 patients, as well as other CoV infections, indicates that the disease results in disproportionate complement activation (<xref rid="t0010" ref-type="table">Table 2</xref>
).<table-wrap position="float" id="t0010"><label>Table 2</label><caption><p>Key studies on complement activation in coronavirus pneumonia.</p></caption><alt-text id="al0015">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Reference</th><th>CoV type</th><th>Key finding</th></tr></thead><tbody><tr><td>Gralinski [<xref rid="bb0350" ref-type="bibr">70</xref>]</td><td>SARS-CoV</td><td>Relative to controls, SARS-CoV-infected C3&#x02212;/&#x02212; mice exhibited less respiratory dysfunction (despite equivalent viral loads in the lung), fewer neutrophils and inflammatory monocytes in the lungs, and reduced lung pathology and lower cytokine and chemokine levels in both the lungs and the sera.</td></tr><tr><td>Jiang [<xref rid="bb0355" ref-type="bibr">71</xref>]</td><td>MERS-CoV</td><td>Complement was excessively activated in MERS-CoV-infected mice through observations of increased concentrations of C5a and C5b-9 in sera and lung tissues, respectively. Blockade of the C5a-C5aR axis lead to the decreased tissue damage.</td></tr><tr><td>Magro [<xref rid="bb0360" ref-type="bibr">72</xref>]</td><td>SARS-CoV-2</td><td>In the examination of tissue from 5 patients with severe COVID-19, significant deposits of C5b-9, C4d and MASP-2 were found in the pulmonary microvasculature. Purpuric skin lesions of 3 patients also showed deposition of C5b-9 and C4d.</td></tr><tr><td>Gao [<xref rid="bb0365" ref-type="bibr">73</xref>]<xref rid="tf0005" ref-type="table-fn">a</xref></td><td>SARS-CoV-2<break/>SARS-CoV<break/>MERS-CoV</td><td>The N proteins of SARS-CoV, MERS-CoV and SARS-CoV-2 were found to bind to MASP-2, resulting in aberrant complement activation and aggravated inflammatory lung injury. Complement hyper-activation was also observed in COVID-19 patients, and a suppressive effect was observed when the deteriorating patients were treated with anti-C5a monoclonal antibody.</td></tr><tr><td>Lam [<xref rid="bb0370" ref-type="bibr">74</xref>]<xref rid="tf0005" ref-type="table-fn">a</xref></td><td>SARS-CoV-2</td><td>Compared to healthy donors, the amount red blood cells with bound C3b and C4d were markedly elevated in hospitalized COVID-19 patients, and had increased even further by day 7.</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: CoV&#x0202f;=&#x0202f;coronavirus, COVID&#x0202f;=&#x0202f;coronavirus disease, MASP&#x0202f;=&#x0202f;mannan-binding lectin serine protease, MERS&#x0202f;=&#x0202f;Middle East respiratory syndrome, SARS&#x0202f;=&#x0202f;severe acute respiratory syndrome.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tf0005"><label>a</label><p id="np0005">Preprint not yet peer-reviewed.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="s0055"><label>6</label><title>Discussion</title><p id="p0085">The aim of this study was to review the literature on complement activation following CoV pneumonia, as well as the crosstalk between the complement and coagulation systems. In short, evidence suggests a range of interactions between the two, with activation of one amplifying activation of the other independent of their respective established pathways. For example, complement factors are able to increase tissue factor activity [<xref rid="bb0020" ref-type="bibr">[4]</xref>, <xref rid="bb0025" ref-type="bibr">[5]</xref>, <xref rid="bb0030" ref-type="bibr">[6]</xref>, <xref rid="bb0035" ref-type="bibr">[7]</xref>, <xref rid="bb0040" ref-type="bibr">[8]</xref>], form activated thrombin from prothrombin [<xref rid="bb0045" ref-type="bibr">[9]</xref>, <xref rid="bb0050" ref-type="bibr">[10]</xref>, <xref rid="bb0055" ref-type="bibr">[11]</xref>], increase platelet activity and aggregation [<xref rid="bb0085" ref-type="bibr">[17]</xref>, <xref rid="bb0090" ref-type="bibr">[18]</xref>, <xref rid="bb0095" ref-type="bibr">[19]</xref>, <xref rid="bb0100" ref-type="bibr">[20]</xref>,<xref rid="bb0185" ref-type="bibr">37</xref>], increase prothrombinase activity and the release of platelet-derived procoagulant granules [<xref rid="bb0105" ref-type="bibr">21</xref>,<xref rid="bb0110" ref-type="bibr">22</xref>], as well as stimulate endothelial cells to release von Willebrand factor and express P-selectin [<xref rid="bb0140" ref-type="bibr">[28]</xref>, <xref rid="bb0145" ref-type="bibr">[29]</xref>, <xref rid="bb0150" ref-type="bibr">[30]</xref>]. Complement also regulates fibrinolysis, with complement cascade inhibitors demonstrating the ability to inhibit plasmin [<xref rid="bb0135" ref-type="bibr">27</xref>], and complement factors able to activate the fibrinolysis inhibitors PAI-1 and TAFI [<xref rid="bb0040" ref-type="bibr">8</xref>,<xref rid="bb0050" ref-type="bibr">10</xref>,<xref rid="bb0055" ref-type="bibr">11</xref>]. This collectively suggests that increased complement activity leads to increased coagulation cascade activity and platelet aggregation, i.e. a prothrombotic state, which is exemplified by a number of complementopathies where inappropriate activation of the complement pathways result in thrombotic complications that can be reduced using complement-inhibitors. In the case of COVID-19, evidence is accumulating of an incidence of VTE, stroke and myocardial injury that is higher than matched ICU cohorts [<xref rid="bb0260" ref-type="bibr">52</xref>,<xref rid="bb0265" ref-type="bibr">53</xref>,<xref rid="bb0340" ref-type="bibr">68</xref>,<xref rid="bb0270" ref-type="bibr">[54]</xref>, <xref rid="bb0275" ref-type="bibr">[55]</xref>, <xref rid="bb0280" ref-type="bibr">[56]</xref>, <xref rid="bb0285" ref-type="bibr">[57]</xref>, <xref rid="bb0290" ref-type="bibr">[58]</xref>, <xref rid="bb0295" ref-type="bibr">[59]</xref>, <xref rid="bb0300" ref-type="bibr">[60]</xref>, <xref rid="bb0305" ref-type="bibr">[61]</xref>]. Intriguingly, early evidence from COVID-19, as well as previous studies on SARS-CoV and MERS-CoV, also indicates that the complement system is overactivated and contributes to the dysregulated host immune response [<xref rid="bb0350" ref-type="bibr">[70]</xref>, <xref rid="bb0355" ref-type="bibr">[71]</xref>, <xref rid="bb0360" ref-type="bibr">[72]</xref>, <xref rid="bb0365" ref-type="bibr">[73]</xref>, <xref rid="bb0370" ref-type="bibr">[74]</xref>]. Although several similarities exist with known complementopathies, there are yet no studies that have examined if there is an interaction between the complement and coagulation system in COVID-19. Based on the material provided in this review, such an interaction would presumably lead to increased thrombosis, and might therefore explain the prothrombotic state seen in these patients.</p></sec><sec id="s0060"><title>Abbreviations</title><p id="p0090">
<def-list><def-item><term id="dt0005"><xref rid="p0060" ref-type="p">aHUS</xref></term><def><p id="p0095">atypical hemolytic uremic syndrome</p></def></def-item><def-item><term id="dt0010"><xref rid="p0070" ref-type="p">ARDS</xref></term><def><p id="p0100">acute respiratory distress syndrome</p></def></def-item><def-item><term id="dt0015"><xref rid="p0040" ref-type="p">C1-INH</xref></term><def><p id="p0105">C1-inhibitor</p></def></def-item><def-item><term id="dt0020"><xref rid="p0035" ref-type="p">C4BP</xref></term><def><p id="p0110">C4b-binding protein</p></def></def-item><def-item><term id="dt0025"><xref rid="p0030" ref-type="p">CoV</xref></term><def><p id="p0115">coronavirus</p></def></def-item><def-item><term id="dt0030">COVID</term><def><p id="p0120">coronavirus disease</p></def></def-item><def-item><term id="dt0035"><xref rid="p0035" ref-type="p">DAF</xref></term><def><p id="p0125">decay-accelerating factor</p></def></def-item><def-item><term id="dt0040"><xref rid="p0065" ref-type="p">DIC</xref></term><def><p id="p0130">disseminated intravascular coagulation</p></def></def-item><def-item><term id="dt0045"><xref rid="p0070" ref-type="p">DVT</xref></term><def><p id="p0135">deep vein thrombosis</p></def></def-item><def-item><term id="dt0050"><xref rid="p0070" ref-type="p">ICU</xref></term><def><p id="p0140">intensive care unit</p></def></def-item><def-item><term id="dt0055"><xref rid="p0035" ref-type="p">MAC</xref></term><def><p id="p0145">membrane attack complex</p></def></def-item><def-item><term id="dt0060">MASP</term><def><p id="p0150">mannan-binding lectin serine protease</p></def></def-item><def-item><term id="dt0065">MERS</term><def><p id="p0155">Middle East respiratory syndrome</p></def></def-item><def-item><term id="dt0070"><xref rid="p0050" ref-type="p">PAI-1</xref></term><def><p id="p0160">plasminogen activator inhibitor-1</p></def></def-item><def-item><term id="dt0075"><xref rid="p0070" ref-type="p">PE</xref></term><def><p id="p0165">pulmonary embolism</p></def></def-item><def-item><term id="dt0080"><xref rid="p0060" ref-type="p">PNH</xref></term><def><p id="p0170">paroxysmal nocturnal hemoglobinuria</p></def></def-item><def-item><term id="dt0085">SARS</term><def><p id="p0175">severe acute respiratory syndrome</p></def></def-item><def-item><term id="dt0090"><xref rid="p0060" ref-type="p">SLE</xref></term><def><p id="p0180">systemic lupus erythematosus</p></def></def-item><def-item><term id="dt0095"><xref rid="p0050" ref-type="p">TAFI</xref></term><def><p id="p0185">thrombin activatable fibrinolysis inhibitor</p></def></def-item><def-item><term id="dt0100">TAT</term><def><p id="p0190">thrombin-antithrombin complex</p></def></def-item><def-item><term id="dt0105"><xref rid="p0070" ref-type="p">VTE</xref></term><def><p id="p0195">venous thromboembolism</p></def></def-item></def-list>
</p></sec><sec id="s0065"><title>Author contributions</title><p id="p0200">Conceptualization: AFS, BMB. Methodology: AFS. Data curation: AFS. Data interpretation: AFS, BMB. Writing&#x02014;original draft preparation: AFS. Writing&#x02014;review and editing: AFS, BMB. Supervision: BMB.</p></sec><sec id="s0070"><title>Funding</title><p id="p0205">Institutional funding only.</p></sec></body><back><ref-list id="bi0005"><title>References</title><ref id="bb0005"><label>1</label><mixed-citation publication-type="other" id="or0005">A.M. Risitano, D.C. Mastellos, M. Huber-Lang, D. Yancopoulou, C. Garlanda, F. Ciceri, J.D. Lambris, Complement as a target in COVID-19?. doi:<pub-id pub-id-type="doi">10.1038/s41577-020-0320-7</pub-id> (n.d.).</mixed-citation></ref><ref id="bb0010"><label>2</label><element-citation publication-type="journal" id="rf0005"><person-group person-group-type="author"><name><surname>Sarma</surname><given-names>J.V.</given-names></name><name><surname>Ward</surname><given-names>P.A.</given-names></name></person-group><article-title>The complement system</article-title><source>Cell Tissue Res.</source><volume>343</volume><year>2011</year><fpage>227</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1007/s00441-010-1034-0</pub-id><pub-id pub-id-type="pmid">20838815</pub-id></element-citation></ref><ref id="bb0015"><label>3</label><element-citation publication-type="journal" id="rf0010"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>N.</given-names></name><name><surname>Li</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Sun</surname><given-names>Z.</given-names></name></person-group><article-title>Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia</article-title><source>J. Thromb. Haemost.</source><volume>18</volume><year>2020</year><fpage>844</fpage><lpage>847</lpage><pub-id pub-id-type="doi">10.1111/jth.14768</pub-id><pub-id pub-id-type="pmid">32073213</pub-id></element-citation></ref><ref id="bb0020"><label>4</label><element-citation publication-type="journal" id="rf0015"><person-group person-group-type="author"><name><surname>Ritis</surname><given-names>K.</given-names></name><name><surname>Doumas</surname><given-names>M.</given-names></name><name><surname>Mastellos</surname><given-names>D.</given-names></name><name><surname>Micheli</surname><given-names>A.</given-names></name><name><surname>Giaglis</surname><given-names>S.</given-names></name><name><surname>Magotti</surname><given-names>P.</given-names></name><name><surname>Rafail</surname><given-names>S.</given-names></name><name><surname>Kartalis</surname><given-names>G.</given-names></name><name><surname>Sideras</surname><given-names>P.</given-names></name><name><surname>Lambris</surname><given-names>J.D.</given-names></name></person-group><article-title>A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways</article-title><source>J. Immunol.</source><volume>177</volume><year>2006</year><fpage>4794</fpage><lpage>4802</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.177.7.4794</pub-id><pub-id pub-id-type="pmid">16982920</pub-id></element-citation></ref><ref id="bb0025"><label>5</label><element-citation publication-type="journal" id="rf0020"><person-group person-group-type="author"><name><surname>Ikeda</surname><given-names>K.</given-names></name><name><surname>Nagasawa</surname><given-names>K.</given-names></name><name><surname>Horiuchi</surname><given-names>T.</given-names></name><name><surname>Tsuru</surname><given-names>T.</given-names></name><name><surname>Nishizaka</surname><given-names>H.</given-names></name><name><surname>Niho</surname><given-names>Y.</given-names></name></person-group><article-title>C5a induces tissue factor activity on endothelial cells</article-title><source>Thromb. Haemost.</source><volume>77</volume><year>1997</year><fpage>394</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1055/s-0038-1655974</pub-id><pub-id pub-id-type="pmid">9157602</pub-id></element-citation></ref><ref id="bb0030"><label>6</label><element-citation publication-type="journal" id="rf0025"><person-group person-group-type="author"><name><surname>Landsem</surname><given-names>A.</given-names></name><name><surname>Fure</surname><given-names>H.</given-names></name><name><surname>Christiansen</surname><given-names>D.</given-names></name><name><surname>Nielsen</surname><given-names>E.W.</given-names></name><name><surname>&#x000d8;sterud</surname><given-names>B.</given-names></name><name><surname>Mollnes</surname><given-names>T.E.</given-names></name><name><surname>Brekke</surname><given-names>O.L.</given-names></name></person-group><article-title>The key roles of complement and tissue factor in Escherichia coli-induced coagulation in human whole blood</article-title><source>Clin. Exp. Immunol.</source><volume>182</volume><year>2015</year><fpage>81</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1111/cei.12663</pub-id><pub-id pub-id-type="pmid">26241501</pub-id></element-citation></ref><ref id="bb0035"><label>7</label><element-citation publication-type="journal" id="rf0030"><person-group person-group-type="author"><name><surname>&#x000d8;vsteb&#x000f8;</surname><given-names>R.</given-names></name><name><surname>Hellum</surname><given-names>M.</given-names></name><name><surname>Aass</surname><given-names>H.C.D.</given-names></name><name><surname>Tr&#x000f8;seid</surname><given-names>A.M.</given-names></name><name><surname>Brandtzaeg</surname><given-names>P.</given-names></name><name><surname>Mollnes</surname><given-names>T.E.</given-names></name><name><surname>Henriksson</surname><given-names>C.E.</given-names></name></person-group><article-title>Microparticle-associated tissue factor activity is reduced by inhibition of the complement protein 5 in Neisseria meningitidis-exposed whole blood</article-title><source>Innate Immun.</source><volume>20</volume><year>2014</year><fpage>552</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1177/1753425913502099</pub-id><pub-id pub-id-type="pmid">24051102</pub-id></element-citation></ref><ref id="bb0040"><label>8</label><element-citation publication-type="journal" id="rf0035"><person-group person-group-type="author"><name><surname>Wojta</surname><given-names>J.</given-names></name><name><surname>Huber</surname><given-names>K.</given-names></name><name><surname>Valent</surname><given-names>P.</given-names></name></person-group><article-title>New aspects in thrombotic research: complement induced switch in mast cells from a profibrinolytic to a prothrombotic phenotype</article-title><source>Pathophysiol. Haemost. Thromb.</source><volume>33</volume><year>2003</year><fpage>438</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.1159/000083842</pub-id><pub-id pub-id-type="pmid">15692257</pub-id></element-citation></ref><ref id="bb0045"><label>9</label><element-citation publication-type="journal" id="rf0040"><person-group person-group-type="author"><name><surname>Krarup</surname><given-names>A.</given-names></name><name><surname>Wallis</surname><given-names>R.</given-names></name><name><surname>Presanis</surname><given-names>J.S.</given-names></name><name><surname>G&#x000e1;l</surname><given-names>P.</given-names></name><name><surname>Sim</surname><given-names>R.B.</given-names></name></person-group><article-title>Simultaneous activation of complement and coagulation by MBL-associated serine protease 2</article-title><source>PLoS One.</source><volume>2</volume><year>2007</year><object-id pub-id-type="publisher-id">e623</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0000623</pub-id></element-citation></ref><ref id="bb0050"><label>10</label><element-citation publication-type="journal" id="rf0045"><person-group person-group-type="author"><name><surname>Hess</surname><given-names>K.</given-names></name><name><surname>Ajjan</surname><given-names>R.</given-names></name><name><surname>Phoenix</surname><given-names>F.</given-names></name><name><surname>Dob&#x000f3;</surname><given-names>J.</given-names></name><name><surname>G&#x000e1;l</surname><given-names>P.</given-names></name><name><surname>Schroeder</surname><given-names>V.</given-names></name></person-group><article-title>Effects of MASP-1 of the complement system on activation of coagulation factors and plasma clot formation</article-title><source>PLoS One.</source><volume>7</volume><year>2012</year><object-id pub-id-type="publisher-id">e35690</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0035690</pub-id></element-citation></ref><ref id="bb0055"><label>11</label><element-citation publication-type="journal" id="rf0050"><person-group person-group-type="author"><name><surname>Dob&#x000f3;</surname><given-names>J.</given-names></name><name><surname>Schroeder</surname><given-names>V.</given-names></name><name><surname>Jenny</surname><given-names>L.</given-names></name><name><surname>Cervenak</surname><given-names>L.</given-names></name><name><surname>Z&#x000e1;vodszky</surname><given-names>P.</given-names></name><name><surname>G&#x000e1;l</surname><given-names>P.</given-names></name></person-group><article-title>Multiple roles of complement MASP-1 at the interface of innate immune response and coagulation</article-title><source>Mol. Immunol.</source><volume>61</volume><year>2014</year><fpage>69</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2014.05.013</pub-id><pub-id pub-id-type="pmid">24935208</pub-id></element-citation></ref><ref id="bb0060"><label>12</label><element-citation publication-type="journal" id="rf0055"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>A.E.</given-names></name></person-group><article-title>Biological effects of C1 inhibitor</article-title><source>Drug News Perspect.</source><volume>17</volume><year>2004</year><fpage>439</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1358/dnp.2004.17.7.863703</pub-id><pub-id pub-id-type="pmid">15514703</pub-id></element-citation></ref><ref id="bb0065"><label>13</label><element-citation publication-type="journal" id="rf0060"><person-group person-group-type="author"><name><surname>Rezende</surname><given-names>S.M.</given-names></name><name><surname>Simmonds</surname><given-names>R.E.</given-names></name><name><surname>Lane</surname><given-names>D.A.</given-names></name></person-group><article-title>Coagulation, inflammation, and apoptosis: different roles for protein S and the protein S-C4b binding protein complex</article-title><source>Blood.</source><volume>103</volume><year>2004</year><fpage>1192</fpage><lpage>1201</lpage><pub-id pub-id-type="doi">10.1182/blood-2003-05-1551</pub-id><pub-id pub-id-type="pmid">12907438</pub-id></element-citation></ref><ref id="bb0070"><label>14</label><element-citation publication-type="journal" id="rf0065"><person-group person-group-type="author"><name><surname>de Agostini</surname><given-names>A.</given-names></name><name><surname>Lijnen</surname><given-names>H.R.</given-names></name><name><surname>Pixley</surname><given-names>R.A.</given-names></name><name><surname>Colman</surname><given-names>R.W.</given-names></name><name><surname>Schapira</surname><given-names>M.</given-names></name></person-group><article-title>Inactivation of factor XII active fragment in normal plasma. Predominant role of C1-inhibitor</article-title><source>J. Clin. Invest.</source><volume>73</volume><year>1984</year><fpage>1542</fpage><lpage>1549</lpage><pub-id pub-id-type="doi">10.1172/JCI111360</pub-id><pub-id pub-id-type="pmid">6725552</pub-id></element-citation></ref><ref id="bb0075"><label>15</label><element-citation publication-type="journal" id="rf0070"><person-group person-group-type="author"><name><surname>Cugno</surname><given-names>M.</given-names></name><name><surname>Bos</surname><given-names>I.</given-names></name><name><surname>Lubbers</surname><given-names>Y.</given-names></name><name><surname>Hack</surname><given-names>C.E.</given-names></name><name><surname>Agostoni</surname><given-names>A.</given-names></name></person-group><article-title>In vitro interaction of C1-inhibitor with thrombin</article-title><source>Blood Coagul. Fibrinolysis.</source><volume>12</volume><year>2001</year><fpage>253</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1097/00001721-200106000-00005</pub-id><pub-id pub-id-type="pmid">11460008</pub-id></element-citation></ref><ref id="bb0080"><label>16</label><element-citation publication-type="journal" id="rf0075"><person-group person-group-type="author"><name><surname>Gushiken</surname><given-names>F.C.</given-names></name><name><surname>Han</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Rumbaut</surname><given-names>R.E.</given-names></name><name><surname>Afshar-Kharghan</surname><given-names>V.</given-names></name></person-group><article-title>Abnormal platelet function in C3-deficient mice</article-title><source>J. Thromb. Haemost.</source><volume>7</volume><year>2009</year><fpage>865</fpage><lpage>870</lpage><pub-id pub-id-type="doi">10.1111/j.1538-7836.2009.03334.x</pub-id><pub-id pub-id-type="pmid">19291167</pub-id></element-citation></ref><ref id="bb0085"><label>17</label><element-citation publication-type="journal" id="rf0080"><person-group person-group-type="author"><name><surname>Polley</surname><given-names>M.J.</given-names></name><name><surname>Nachman</surname><given-names>R.L.</given-names></name></person-group><article-title>Human complement in thrombin-mediated platelet function: uptake of the C5b-9 complex</article-title><source>J. Exp. Med.</source><volume>150</volume><year>1979</year><fpage>633</fpage><lpage>645</lpage><pub-id pub-id-type="pmid">479764</pub-id></element-citation></ref><ref id="bb0090"><label>18</label><element-citation publication-type="journal" id="rf0085"><person-group person-group-type="author"><name><surname>Sims</surname><given-names>P.J.</given-names></name><name><surname>Faioni</surname><given-names>E.M.</given-names></name><name><surname>Wiedmer</surname><given-names>T.</given-names></name><name><surname>Shattil</surname><given-names>S.J.</given-names></name></person-group><article-title>Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity</article-title><source>J. Biol. Chem.</source><volume>263</volume><year>1988</year><fpage>18205</fpage><lpage>18212</lpage><pub-id pub-id-type="pmid">2848029</pub-id></element-citation></ref><ref id="bb0095"><label>19</label><element-citation publication-type="journal" id="rf0090"><person-group person-group-type="author"><name><surname>Polley</surname><given-names>M.J.</given-names></name><name><surname>Nachman</surname><given-names>R.</given-names></name></person-group><article-title>The human complement system in thrombin-mediated platelet function</article-title><source>J. Exp. Med.</source><volume>147</volume><year>1978</year><fpage>1713</fpage><lpage>1726</lpage><pub-id pub-id-type="pmid">681879</pub-id></element-citation></ref><ref id="bb0100"><label>20</label><element-citation publication-type="journal" id="rf0095"><person-group person-group-type="author"><name><surname>Subramaniam</surname><given-names>S.</given-names></name><name><surname>Jurk</surname><given-names>K.</given-names></name><name><surname>Hobohm</surname><given-names>L.</given-names></name><name><surname>Jackel</surname><given-names>S.</given-names></name><name><surname>Saffarzadeh</surname><given-names>M.</given-names></name><name><surname>Schwierczek</surname><given-names>K.</given-names></name><name><surname>Wenzel</surname><given-names>P.</given-names></name><name><surname>Langer</surname><given-names>F.</given-names></name><name><surname>Reinhardt</surname><given-names>C.</given-names></name><name><surname>Ruf</surname><given-names>W.</given-names></name></person-group><article-title>Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development</article-title><source>Blood.</source><volume>129</volume><year>2017</year><fpage>2291</fpage><lpage>2302</lpage><pub-id pub-id-type="doi">10.1182/blood-2016-11-749879</pub-id><pub-id pub-id-type="pmid">28223279</pub-id></element-citation></ref><ref id="bb0105"><label>21</label><element-citation publication-type="journal" id="rf0100"><person-group person-group-type="author"><name><surname>Wiedmer</surname><given-names>T.</given-names></name><name><surname>Esmon</surname><given-names>C.T.</given-names></name><name><surname>Sims</surname><given-names>P.J.</given-names></name></person-group><article-title>On the mechanism by which complement proteins C5b-9 increase platelet prothrombinase activity</article-title><source>J. Biol. Chem.</source><volume>261</volume><year>1986</year><fpage>14587</fpage><lpage>14592</lpage><pub-id pub-id-type="pmid">3155419</pub-id></element-citation></ref><ref id="bb0110"><label>22</label><element-citation publication-type="journal" id="rf0105"><person-group person-group-type="author"><name><surname>Wiedmer</surname><given-names>T.</given-names></name><name><surname>Esmon</surname><given-names>C.T.</given-names></name><name><surname>Sims</surname><given-names>P.J.</given-names></name></person-group><article-title>Complement proteins C5b-9 stimulate procoagulant activity through platelet prothrombinase</article-title><source>Blood.</source><volume>68</volume><year>1986</year><fpage>875</fpage><lpage>880</lpage><pub-id pub-id-type="pmid">3092889</pub-id></element-citation></ref><ref id="bb0115"><label>23</label><element-citation publication-type="journal" id="rf0110"><person-group person-group-type="author"><name><surname>Atefi</surname><given-names>G.</given-names></name><name><surname>Aisiku</surname><given-names>O.</given-names></name><name><surname>Shapiro</surname><given-names>N.</given-names></name><name><surname>Hauser</surname><given-names>C.</given-names></name><name><surname>Lucca</surname><given-names>D.</given-names></name><name><surname>Flaumenhaft</surname><given-names>R.</given-names></name><name><surname>Tsokos</surname><given-names>G.C.</given-names></name><name><surname>Dalle Lucca</surname><given-names>J.</given-names></name><name><surname>Flaumenhaft</surname><given-names>R.</given-names></name><name><surname>Tsokos</surname><given-names>G.C.</given-names></name></person-group><article-title>Complement activation in trauma patients alters platelet function</article-title><source>Shock.</source><volume>46</volume><year>2016</year><fpage>83</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1097/SHK.0000000000000675</pub-id></element-citation></ref><ref id="bb0120"><label>24</label><element-citation publication-type="journal" id="rf0115"><person-group person-group-type="author"><name><surname>Fletcher-Sandersj&#x000f6;&#x000f6;</surname><given-names>A.</given-names></name><name><surname>Maegele</surname><given-names>M.</given-names></name><name><surname>Bellander</surname><given-names>B.-M.</given-names></name></person-group><article-title>Does complement-mediated hemostatic disturbance occur in traumatic brain injury? A literature review and observational study protocol</article-title><source>Int. J. Mol. Sci.</source><volume>21</volume><year>2020</year><fpage>1596</fpage><pub-id pub-id-type="doi">10.3390/ijms21051596</pub-id></element-citation></ref><ref id="bb0125"><label>25</label><element-citation publication-type="journal" id="rf0120"><person-group person-group-type="author"><name><surname>Huber-Lang</surname><given-names>M.</given-names></name><name><surname>Kovtun</surname><given-names>A.</given-names></name><name><surname>Ignatius</surname><given-names>A.</given-names></name></person-group><article-title>The role of complement in trauma and fracture healing</article-title><source>Semin. Immunol.</source><volume>25</volume><year>2013</year><fpage>73</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/j.smim.2013.05.006</pub-id><pub-id pub-id-type="pmid">23768898</pub-id></element-citation></ref><ref id="bb0130"><label>26</label><element-citation publication-type="journal" id="rf0125"><person-group person-group-type="author"><name><surname>van Griensven</surname><given-names>M.</given-names></name><name><surname>Ricklin</surname><given-names>D.</given-names></name><name><surname>Denk</surname><given-names>S.</given-names></name><name><surname>Halbgebauer</surname><given-names>R.</given-names></name><name><surname>Braun</surname><given-names>C.K.</given-names></name><name><surname>Schultze</surname><given-names>A.</given-names></name><name><surname>H&#x000f6;nes</surname><given-names>F.</given-names></name><name><surname>Koutsogiannaki</surname><given-names>S.</given-names></name><name><surname>Primikyri</surname><given-names>A.</given-names></name><name><surname>Reis</surname><given-names>E.</given-names></name><name><surname>Messerer</surname><given-names>D.</given-names></name><name><surname>Hafner</surname><given-names>S.</given-names></name><name><surname>Radermacher</surname><given-names>P.</given-names></name><name><surname>Biglarnia</surname><given-names>A.R.</given-names></name><name><surname>Resuello</surname><given-names>R.R.G.</given-names></name><name><surname>Tuplano</surname><given-names>J.V.</given-names></name><name><surname>Mayer</surname><given-names>B.</given-names></name><name><surname>Nilsson</surname><given-names>K.</given-names></name><name><surname>Nilsson</surname><given-names>B.</given-names></name><name><surname>Lambris</surname><given-names>J.D.</given-names></name><name><surname>Huber-Lang</surname><given-names>M.</given-names></name></person-group><article-title>Protective effects of the complement inhibitor compstatin CP40 in hemorrhagic shock</article-title><source>Shock.</source><volume>51</volume><year>2019</year><fpage>78</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1097/SHK.0000000000001127</pub-id><pub-id pub-id-type="pmid">29461464</pub-id></element-citation></ref><ref id="bb0135"><label>27</label><element-citation publication-type="journal" id="rf0130"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>E.W.</given-names></name><name><surname>Ravindran</surname><given-names>S.</given-names></name><name><surname>Patston</surname><given-names>P.A.</given-names></name></person-group><article-title>The reaction between plasmin and C1-inhibitor results in plasmin inhibition by the serpin mechanism</article-title><source>Blood Coagul. Fibrinolysis.</source><volume>13</volume><year>2002</year><fpage>711</fpage><lpage>714</lpage><pub-id pub-id-type="doi">10.1097/00001721-200212000-00007</pub-id><pub-id pub-id-type="pmid">12441910</pub-id></element-citation></ref><ref id="bb0140"><label>28</label><element-citation publication-type="journal" id="rf0135"><person-group person-group-type="author"><name><surname>Hattori</surname><given-names>R.</given-names></name><name><surname>Hamilton</surname><given-names>K.K.</given-names></name><name><surname>McEver</surname><given-names>R.P.</given-names></name><name><surname>Sims</surname><given-names>P.J.</given-names></name></person-group><article-title>Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface</article-title><source>J. Biol. Chem.</source><volume>264</volume><year>1989</year><fpage>9053</fpage><lpage>9060</lpage><pub-id pub-id-type="pmid">2470750</pub-id></element-citation></ref><ref id="bb0145"><label>29</label><element-citation publication-type="journal" id="rf0140"><person-group person-group-type="author"><name><surname>Hamilton</surname><given-names>K.K.</given-names></name><name><surname>Hattori</surname><given-names>R.</given-names></name><name><surname>Esmon</surname><given-names>C.T.</given-names></name><name><surname>Sims</surname><given-names>P.J.</given-names></name></person-group><article-title>Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex</article-title><source>J. Biol. Chem.</source><volume>265</volume><year>1990</year><fpage>3809</fpage><lpage>3814</lpage><pub-id pub-id-type="pmid">2105954</pub-id></element-citation></ref><ref id="bb0150"><label>30</label><element-citation publication-type="journal" id="rf0145"><person-group person-group-type="author"><name><surname>Foreman</surname><given-names>K.E.</given-names></name><name><surname>Vaporciyan</surname><given-names>A.A.</given-names></name><name><surname>Bonish</surname><given-names>B.K.</given-names></name><name><surname>Jones</surname><given-names>M.L.</given-names></name><name><surname>Johnson</surname><given-names>K.J.</given-names></name><name><surname>Glovsky</surname><given-names>M.M.</given-names></name><name><surname>Eddy</surname><given-names>S.M.</given-names></name><name><surname>Ward</surname><given-names>P.A.</given-names></name></person-group><article-title>C5a-induced expression of P-selectin in endothelial cells</article-title><source>J. Clin. Invest.</source><volume>94</volume><year>1994</year><fpage>1147</fpage><lpage>1155</lpage><pub-id pub-id-type="doi">10.1172/JCI117430</pub-id><pub-id pub-id-type="pmid">7521884</pub-id></element-citation></ref><ref id="bb0155"><label>31</label><element-citation publication-type="journal" id="rf0150"><person-group person-group-type="author"><name><surname>Hammad</surname><given-names>A.</given-names></name><name><surname>Westacott</surname><given-names>L.</given-names></name><name><surname>Zaben</surname><given-names>M.</given-names></name></person-group><article-title>The role of the complement system in traumatic brain injury: a review</article-title><source>J. Neuroinflammation.</source><volume>15</volume><year>2018</year><pub-id pub-id-type="doi">10.1186/s12974-018-1066-z</pub-id></element-citation></ref><ref id="bb0160"><label>32</label><element-citation publication-type="journal" id="rf0155"><person-group person-group-type="author"><name><surname>Huber-Lang</surname><given-names>M.</given-names></name><name><surname>Lambris</surname><given-names>J.D.</given-names></name><name><surname>Ward</surname><given-names>P.A.</given-names></name></person-group><article-title>Innate immune responses to trauma review-article</article-title><source>Nat. Immunol.</source><volume>19</volume><year>2018</year><fpage>327</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1038/s41590-018-0064-8</pub-id><pub-id pub-id-type="pmid">29507356</pub-id></element-citation></ref><ref id="bb0165"><label>33</label><element-citation publication-type="journal" id="rf0160"><person-group person-group-type="author"><name><surname>Krem</surname><given-names>M.M.</given-names></name><name><surname>Di Cera</surname><given-names>E.</given-names></name></person-group><article-title>Evolution of enzyme cascades from embryonic development to blood coagulation</article-title><source>Trends Biochem. Sci.</source><volume>27</volume><year>2002</year><fpage>67</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/s0968-0004(01)02007-2</pub-id><pub-id pub-id-type="pmid">11852243</pub-id></element-citation></ref><ref id="bb0170"><label>34</label><element-citation publication-type="journal" id="rf0165"><person-group person-group-type="author"><name><surname>Merle</surname><given-names>N.S.</given-names></name><name><surname>Noe</surname><given-names>R.</given-names></name><name><surname>Halbwachs-Mecarelli</surname><given-names>L.</given-names></name><name><surname>Fremeaux-Bacchi</surname><given-names>V.</given-names></name><name><surname>Roumenina</surname><given-names>L.T.</given-names></name></person-group><article-title>Complement system part II: role in immunity</article-title><source>Front. Immunol.</source><volume>6</volume><year>2015</year><pub-id pub-id-type="doi">10.3389/fimmu.2015.00257</pub-id></element-citation></ref><ref id="bb0175"><label>35</label><element-citation publication-type="journal" id="rf0170"><person-group person-group-type="author"><name><surname>Afshar-Kharghan</surname><given-names>V.</given-names></name></person-group><article-title>The role of the complement system in cancer</article-title><source>J. Clin. Invest.</source><volume>127</volume><year>2017</year><fpage>780</fpage><lpage>789</lpage><pub-id pub-id-type="doi">10.1172/JCI90962</pub-id><pub-id pub-id-type="pmid">28248200</pub-id></element-citation></ref><ref id="bb0180"><label>36</label><element-citation publication-type="journal" id="rf0175"><person-group person-group-type="author"><name><surname>Dzik</surname><given-names>S.</given-names></name></person-group><article-title>Complement and coagulation: cross talk through time</article-title><source>Transfus. Med. Rev.</source><volume>33</volume><year>2019</year><fpage>199</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1016/j.tmrv.2019.08.004</pub-id><pub-id pub-id-type="pmid">31672340</pub-id></element-citation></ref><ref id="bb0185"><label>37</label><element-citation publication-type="journal" id="rf0180"><person-group person-group-type="author"><name><surname>Sauter</surname><given-names>R.J.</given-names></name><name><surname>Sauter</surname><given-names>M.</given-names></name></person-group><article-title>Functional relevance of the Anaphylatoxin receptor C3aR for platelet function and arterial thrombus formation marks an intersection point between innate immunity and thrombosis</article-title><source>Circulation.</source><volume>138</volume><year>2018</year><fpage>1720</fpage><lpage>1735</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.118.034600</pub-id><pub-id pub-id-type="pmid">29802205</pub-id></element-citation></ref><ref id="bb0190"><label>38</label><element-citation publication-type="journal" id="rf0185"><person-group person-group-type="author"><name><surname>Amara</surname><given-names>U.</given-names></name><name><surname>Rittirsch</surname><given-names>D.</given-names></name><name><surname>Flierl</surname><given-names>M.</given-names></name><name><surname>Bruckner</surname><given-names>U.</given-names></name><name><surname>Klos</surname><given-names>A.</given-names></name><name><surname>Gebhard</surname><given-names>F.</given-names></name><name><surname>Lambris</surname><given-names>J.D.</given-names></name><name><surname>Huber-Lang</surname><given-names>M.</given-names></name></person-group><article-title>Interaction between the coagulation and complement system</article-title><source>Adv. Exp. Med. Biol.</source><volume>632</volume><year>2008</year><fpage>71</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">19025115</pub-id></element-citation></ref><ref id="bb0195"><label>39</label><element-citation publication-type="journal" id="rf0190"><person-group person-group-type="author"><name><surname>Huber-Lang</surname><given-names>M.</given-names></name><name><surname>Sarma</surname><given-names>J.V.</given-names></name><name><surname>Zetoune</surname><given-names>F.S.</given-names></name><name><surname>Rittirsch</surname><given-names>D.</given-names></name><name><surname>Neff</surname><given-names>T.A.</given-names></name><name><surname>McGuire</surname><given-names>S.R.</given-names></name><name><surname>Lambris</surname><given-names>J.D.</given-names></name><name><surname>Warner</surname><given-names>R.L.</given-names></name><name><surname>Flierl</surname><given-names>M.A.</given-names></name><name><surname>Hoesel</surname><given-names>L.M.</given-names></name><name><surname>Gebhard</surname><given-names>F.</given-names></name><name><surname>Younger</surname><given-names>J.G.</given-names></name><name><surname>Drouin</surname><given-names>S.M.</given-names></name><name><surname>Wetsel</surname><given-names>R.A.</given-names></name><name><surname>Ward</surname><given-names>P.A.</given-names></name></person-group><article-title>Generation of C5a in the absence of C3: a new complement activation pathway</article-title><source>Nat. Med.</source><volume>12</volume><year>2006</year><fpage>682</fpage><lpage>687</lpage><pub-id pub-id-type="doi">10.1038/nm1419</pub-id><pub-id pub-id-type="pmid">16715088</pub-id></element-citation></ref><ref id="bb0200"><label>40</label><element-citation publication-type="journal" id="rf0195"><person-group person-group-type="author"><name><surname>Amara</surname><given-names>U.</given-names></name><name><surname>Flierl</surname><given-names>M.A.</given-names></name><name><surname>Rittirsch</surname><given-names>D.</given-names></name><name><surname>Klos</surname><given-names>A.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Acker</surname><given-names>B.</given-names></name><name><surname>Br&#x000fc;ckner</surname><given-names>U.B.</given-names></name><name><surname>Nilsson</surname><given-names>B.</given-names></name><name><surname>Gebhard</surname><given-names>F.</given-names></name><name><surname>Lambris</surname><given-names>J.D.</given-names></name><name><surname>Huber-Lang</surname><given-names>M.</given-names></name></person-group><article-title>Molecular intercommunication between the complement and coagulation systems</article-title><source>J. Immunol.</source><volume>185</volume><year>2010</year><fpage>5628</fpage><lpage>5636</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0903678</pub-id><pub-id pub-id-type="pmid">20870944</pub-id></element-citation></ref><ref id="bb0205"><label>41</label><element-citation publication-type="journal" id="rf0200"><person-group person-group-type="author"><name><surname>Foley</surname><given-names>J.H.</given-names></name><name><surname>Conway</surname><given-names>E.M.</given-names></name></person-group><article-title>Cross talk pathways between coagulation and inflammation</article-title><source>Circ. Res.</source><volume>118</volume><year>2016</year><fpage>1392</fpage><lpage>1408</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.306853</pub-id><pub-id pub-id-type="pmid">27126649</pub-id></element-citation></ref><ref id="bb0210"><label>42</label><element-citation publication-type="journal" id="rf0205"><person-group person-group-type="author"><name><surname>Foley</surname><given-names>J.H.</given-names></name><name><surname>Walton</surname><given-names>B.L.</given-names></name><name><surname>Aleman</surname><given-names>M.M.</given-names></name><name><surname>O'Byrne</surname><given-names>A.M.</given-names></name><name><surname>Lei</surname><given-names>V.</given-names></name><name><surname>Harrasser</surname><given-names>M.</given-names></name><name><surname>Foley</surname><given-names>K.A.</given-names></name><name><surname>Wolberg</surname><given-names>A.S.</given-names></name><name><surname>Conway</surname><given-names>E.M.</given-names></name></person-group><article-title>Complement activation in arterial and venous thrombosis is mediated by plasmin</article-title><source>EBioMedicine.</source><volume>5</volume><year>2016</year><fpage>175</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2016.02.011</pub-id><pub-id pub-id-type="pmid">27077125</pub-id></element-citation></ref><ref id="bb0215"><label>43</label><element-citation publication-type="journal" id="rf0210"><person-group person-group-type="author"><name><surname>Sardu</surname><given-names>C.</given-names></name><name><surname>Gambardella</surname><given-names>J.</given-names></name><name><surname>Morelli</surname><given-names>M.B.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Marfella</surname><given-names>R.</given-names></name><name><surname>Santulli</surname><given-names>G.</given-names></name></person-group><article-title>Is COVID-19 an endothelial disease? Clinical and basic evidence</article-title><source>Clin. Basic Evid.</source><year>2020</year><pub-id pub-id-type="doi">10.20944/PREPRINTS202004.0204.V1</pub-id></element-citation></ref><ref id="bb0220"><label>44</label><element-citation publication-type="journal" id="rf0215"><person-group person-group-type="author"><name><surname>Merrill</surname><given-names>S.A.</given-names></name><name><surname>Brodsky</surname><given-names>R.A.</given-names></name></person-group><article-title>Complement-driven anemia: more than just paroxysmal nocturnal hemoglobinuria</article-title><source>Hematology.</source><volume>2018</volume><year>2018</year><fpage>371</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1182/asheducation-2018.1.371</pub-id><pub-id pub-id-type="pmid">30504334</pub-id></element-citation></ref><ref id="bb0225"><label>45</label><element-citation publication-type="journal" id="rf0220"><person-group person-group-type="author"><name><surname>Chapin</surname><given-names>J.</given-names></name><name><surname>Terry</surname><given-names>H.S.</given-names></name><name><surname>Kleinert</surname><given-names>D.</given-names></name><name><surname>Laurence</surname><given-names>J.</given-names></name></person-group><article-title>The role of complement activation in thrombosis and hemolytic anemias</article-title><source>Transfus. Apher. Sci.</source><volume>54</volume><year>2016</year><fpage>191</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1016/j.transci.2016.04.008</pub-id><pub-id pub-id-type="pmid">27156108</pub-id></element-citation></ref><ref id="bb0230"><label>46</label><element-citation publication-type="journal" id="rf0225"><person-group person-group-type="author"><name><surname>Eriksson</surname><given-names>O.</given-names></name><name><surname>Mohlin</surname><given-names>C.</given-names></name><name><surname>Nilsson</surname><given-names>B.</given-names></name><name><surname>Ekdahl</surname><given-names>K.N.</given-names></name></person-group><article-title>The human platelet as an innate immune cell: interactions between activated platelets and the complement system</article-title><source>Front. Immunol.</source><volume>10</volume><year>2019</year><pub-id pub-id-type="doi">10.3389/fimmu.2019.01590</pub-id></element-citation></ref><ref id="bb0235"><label>47</label><element-citation publication-type="journal" id="rf0230"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>N.</given-names></name><name><surname>Uchino</surname><given-names>K.</given-names></name><name><surname>Fakhran</surname><given-names>S.</given-names></name><name><surname>Sattar</surname><given-names>M.A.</given-names></name><name><surname>Branstetter</surname><given-names>B.F.</given-names></name><name><surname>Au</surname><given-names>K.</given-names></name><name><surname>Navratil</surname><given-names>J.S.</given-names></name><name><surname>Paul</surname><given-names>B.</given-names></name><name><surname>Lee</surname><given-names>M.</given-names></name><name><surname>Gallagher</surname><given-names>K.M.</given-names></name><name><surname>Manzi</surname><given-names>S.</given-names></name><name><surname>Ahearn</surname><given-names>J.M.</given-names></name><name><surname>Kao</surname><given-names>A.H.</given-names></name></person-group><article-title>Platelet C4d is associated with acute ischemic stroke and stroke severity</article-title><source>Stroke.</source><volume>39</volume><year>2008</year><fpage>3236</fpage><lpage>3241</lpage><pub-id pub-id-type="doi">10.1161/STROKEAHA.108.514687</pub-id><pub-id pub-id-type="pmid">18927458</pub-id></element-citation></ref><ref id="bb0240"><label>48</label><element-citation publication-type="journal" id="rf0235"><person-group person-group-type="author"><name><surname>Petri</surname><given-names>M.A.</given-names></name><name><surname>Conklin</surname><given-names>J.</given-names></name><name><surname>O'Malley</surname><given-names>T.</given-names></name><name><surname>Dervieux</surname><given-names>T.</given-names></name></person-group><article-title>Platelet-bound C4d, low C3 and lupus anticoagulant associate with thrombosis in SLE</article-title><source>Lupus Sci. Med.</source><volume>6</volume><year>2019</year><pub-id pub-id-type="doi">10.1136/lupus-2019-000318</pub-id></element-citation></ref><ref id="bb0245"><label>49</label><element-citation publication-type="journal" id="rf0240"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>A.</given-names></name><name><surname>Dezern</surname><given-names>A.E.</given-names></name><name><surname>Kinoshita</surname><given-names>T.</given-names></name><name><surname>Brodsky</surname><given-names>R.A.</given-names></name></person-group><article-title>Paroxysmal nocturnal haemoglobinuria</article-title><source>Nat. Rev. Dis. Prim.</source><volume>3</volume><year>2017</year><pub-id pub-id-type="doi">10.1038/nrdp.2017.28</pub-id></element-citation></ref><ref id="bb0250"><label>50</label><element-citation publication-type="journal" id="rf0245"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>K.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Harley</surname><given-names>K.T.</given-names></name><name><surname>Tran</surname><given-names>M.H.</given-names></name></person-group><article-title>Atypical hemolytic uremic syndrome: a brief review</article-title><source>Hematol. Rep.</source><volume>9</volume><year>2017</year><fpage>62</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.4081/hr.2017.7053</pub-id></element-citation></ref><ref id="bb0255"><label>51</label><element-citation publication-type="journal" id="rf0250"><person-group person-group-type="author"><name><surname>Abe</surname><given-names>T.</given-names></name><name><surname>Sasaki</surname><given-names>A.</given-names></name><name><surname>Ueda</surname><given-names>T.</given-names></name><name><surname>Miyakawa</surname><given-names>Y.</given-names></name><name><surname>Ochiai</surname><given-names>H.</given-names></name></person-group><article-title>Complement-mediated thrombotic microangiopathy secondary to sepsis-induced disseminated intravascular coagulation successfully treated with eculizumab a case report</article-title><source>Med. (United States)</source><volume>96</volume><year>2017</year><pub-id pub-id-type="doi">10.1097/MD.0000000000006056</pub-id></element-citation></ref><ref id="bb0260"><label>52</label><element-citation publication-type="journal" id="rf0255"><person-group person-group-type="author"><name><surname>Kollias</surname><given-names>A.</given-names></name><name><surname>Kyriakoulis</surname><given-names>K.G.</given-names></name><name><surname>Dimakakos</surname><given-names>E.</given-names></name><name><surname>Poulakou</surname><given-names>G.</given-names></name><name><surname>Stergiou</surname><given-names>G.S.</given-names></name><name><surname>Syrigos</surname><given-names>K.</given-names></name></person-group><article-title>Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action</article-title><source>Br. J. Haematol.</source><year>2020</year><pub-id pub-id-type="doi">10.1111/bjh.16727</pub-id></element-citation></ref><ref id="bb0265"><label>53</label><element-citation publication-type="journal" id="rf0260"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>S.</given-names></name><name><surname>Chen</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>F.</given-names></name></person-group><article-title>Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia</article-title><source>J. Thromb. Haemost.</source><year>2020</year><pub-id pub-id-type="doi">10.1111/jth.14830</pub-id></element-citation></ref><ref id="bb0270"><label>54</label><element-citation publication-type="journal" id="rf0265"><person-group person-group-type="author"><name><surname>Klok</surname><given-names>F.A.</given-names></name><name><surname>Kruip</surname><given-names>M.J.H.A.</given-names></name><name><surname>van der Meer</surname><given-names>N.J.M.</given-names></name><name><surname>Arbous</surname><given-names>M.S.</given-names></name><name><surname>Gommers</surname><given-names>D.A.M.P.J.</given-names></name><name><surname>Kant</surname><given-names>K.M.</given-names></name><name><surname>Kaptein</surname><given-names>F.H.J.</given-names></name><name><surname>van Paassen</surname><given-names>J.</given-names></name><name><surname>Stals</surname><given-names>M.A.M.</given-names></name><name><surname>Huisman</surname><given-names>M.V.</given-names></name><name><surname>Endeman</surname><given-names>H.</given-names></name></person-group><article-title>Incidence of thrombotic complications in critically ill ICU patients with COVID-19</article-title><source>Thromb. Res.</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.thromres.2020.04.013</pub-id></element-citation></ref><ref id="bb0275"><label>55</label><element-citation publication-type="journal" id="rf0270"><person-group person-group-type="author"><name><surname>Helms</surname><given-names>J.</given-names></name><name><surname>Tacquard</surname><given-names>C.</given-names></name><name><surname>Severac</surname><given-names>F.</given-names></name><name><surname>Leonard-Lorant</surname><given-names>I.</given-names></name><name><surname>Ohana</surname><given-names>M.</given-names></name><name><surname>Delabranche</surname><given-names>X.</given-names></name><name><surname>Merdji</surname><given-names>H.</given-names></name><name><surname>Clere-Jehl</surname><given-names>R.</given-names></name><name><surname>Schenck</surname><given-names>M.</given-names></name><name><surname>Fagot Gandet</surname><given-names>F.</given-names></name><name><surname>Fafi-Kremer</surname><given-names>S.</given-names></name><name><surname>Castelain</surname><given-names>V.</given-names></name><name><surname>Schneider</surname><given-names>F.</given-names></name><name><surname>Grunebaum</surname><given-names>L.</given-names></name><name><surname>Angl&#x000e9;s-Cano</surname><given-names>E.</given-names></name><name><surname>Sattler</surname><given-names>L.</given-names></name><name><surname>Mertes</surname><given-names>P.-M.</given-names></name><name><surname>Meziani</surname><given-names>F.</given-names></name></person-group><article-title>High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study</article-title><source>Intensive Care Med.</source><year>2020</year><pub-id pub-id-type="doi">10.1007/s00134-020-06062-x</pub-id></element-citation></ref><ref id="bb0280"><label>56</label><element-citation publication-type="journal" id="rf0275"><person-group person-group-type="author"><name><surname>Edler</surname><given-names>C.</given-names></name><name><surname>Schr&#x000f6;der</surname><given-names>A.S.</given-names></name><name><surname>Aepfelbacher</surname><given-names>M.</given-names></name><name><surname>Fitzek</surname><given-names>A.</given-names></name><name><surname>Heinemann</surname><given-names>A.</given-names></name><name><surname>Heinrich</surname><given-names>F.</given-names></name><name><surname>Klein</surname><given-names>A.</given-names></name><name><surname>Langenwalder</surname><given-names>F.</given-names></name><name><surname>L&#x000fc;tgehetmann</surname><given-names>M.</given-names></name><name><surname>Mei&#x000df;ner</surname><given-names>K.</given-names></name><name><surname>P&#x000fc;schel</surname><given-names>K.</given-names></name><name><surname>Sch&#x000e4;dler</surname><given-names>J.</given-names></name><name><surname>Steurer</surname><given-names>S.</given-names></name><name><surname>Mushumba</surname><given-names>H.</given-names></name><name><surname>Sperhake</surname><given-names>J.-P.</given-names></name></person-group><article-title>Dying with SARS-CoV-2 infection-an autopsy study of the first consecutive 80 cases in Hamburg, Germany</article-title><source>Int. J. Legal Med.</source><year>2020</year><pub-id pub-id-type="doi">10.1007/s00414-020-02317-w</pub-id></element-citation></ref><ref id="bb0285"><label>57</label><element-citation publication-type="journal" id="rf0280"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>L.</given-names></name><name><surname>Jin</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>S.</given-names></name><name><surname>He</surname><given-names>Q.</given-names></name><name><surname>Chang</surname><given-names>J.</given-names></name><name><surname>Hong</surname><given-names>C.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Miao</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name></person-group><article-title>Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China</article-title><source>JAMA Neurol.</source><year>2020</year><pub-id pub-id-type="doi">10.1001/jamaneurol.2020.1127</pub-id></element-citation></ref><ref id="bb0290"><label>58</label><element-citation publication-type="book" id="rf0285"><person-group person-group-type="author"><name><surname>Merkler</surname><given-names>A.E.</given-names></name><name><surname>Parikh</surname><given-names>N.S.</given-names></name><name><surname>Mir</surname><given-names>S.</given-names></name><name><surname>Gupta</surname><given-names>A.</given-names></name><name><surname>Kamel</surname><given-names>H.</given-names></name><name><surname>Lin</surname><given-names>E.</given-names></name><name><surname>Lantos</surname><given-names>J.</given-names></name><name><surname>Schenck</surname><given-names>E.J.</given-names></name><name><surname>Goyal</surname><given-names>P.</given-names></name><name><surname>Bruce</surname><given-names>S.S.</given-names></name><name><surname>Kahan</surname><given-names>J.</given-names></name><name><surname>Lansdale</surname><given-names>K.N.</given-names></name><name><surname>LeMoss</surname><given-names>N.M.</given-names></name><name><surname>Murthy</surname><given-names>S.B.</given-names></name><name><surname>Stieg</surname><given-names>P.E.</given-names></name><name><surname>Fink</surname><given-names>M.E.</given-names></name><name><surname>Iadecola</surname><given-names>C.</given-names></name><name><surname>Segal</surname><given-names>A.Z.</given-names></name><name><surname>Campion</surname><given-names>T.R.</given-names></name><name><surname>Diaz</surname><given-names>I.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Navi</surname><given-names>B.B.</given-names></name></person-group><chapter-title>Risk of Ischemic Stroke in Patients With Covid-19 Versus Patients With Influenza</chapter-title><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.05.18.20105494</pub-id></element-citation></ref><ref id="bb0295"><label>59</label><element-citation publication-type="journal" id="rf0290"><person-group person-group-type="author"><name><surname>Bavishi</surname><given-names>C.</given-names></name><name><surname>Bonow</surname><given-names>R.O.</given-names></name><name><surname>Trivedi</surname><given-names>V.</given-names></name><name><surname>Abbott</surname><given-names>J.D.</given-names></name><name><surname>Messerli</surname><given-names>F.H.</given-names></name><name><surname>Bhatt</surname><given-names>D.L.</given-names></name></person-group><article-title>Acute myocardial injury in patients hospitalized with COVID-19 infection: a review</article-title><source>Prog. Cardiovasc. Dis.</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.pcad.2020.05.013</pub-id></element-citation></ref><ref id="bb0300"><label>60</label><element-citation publication-type="journal" id="rf0295"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>K.</given-names></name><name><surname>Fang</surname><given-names>Y.-Y.</given-names></name><name><surname>Shang</surname><given-names>J.</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>K.</given-names></name><name><surname>Leng</surname><given-names>F.</given-names></name><name><surname>Wei</surname><given-names>S.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>H.-G.</given-names></name></person-group><article-title>Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China</article-title><source>Chin. Med. J. (Engl.)</source><year>2020</year><fpage>1</fpage><pub-id pub-id-type="doi">10.1097/cm9.0000000000000824</pub-id><pub-id pub-id-type="pmid">31923098</pub-id></element-citation></ref><ref id="bb0305"><label>61</label><element-citation publication-type="journal" id="rf0300"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>F.</given-names></name><name><surname>Yu</surname><given-names>T.</given-names></name><name><surname>Du</surname><given-names>R.</given-names></name><name><surname>Fan</surname><given-names>G.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Xiang</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Song</surname><given-names>B.</given-names></name><name><surname>Gu</surname><given-names>X.</given-names></name><name><surname>Guan</surname><given-names>L.</given-names></name><name><surname>Wei</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Tu</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Cao</surname><given-names>B.</given-names></name></person-group><article-title>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study</article-title><source>Lancet.</source><volume>395</volume><year>2020</year><fpage>1054</fpage><lpage>1062</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30566-3</pub-id><pub-id pub-id-type="pmid">32171076</pub-id></element-citation></ref><ref id="bb0310"><label>62</label><element-citation publication-type="journal" id="rf0305"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>W.</given-names></name><name><surname>Ni</surname><given-names>Z.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Liang</surname><given-names>W.</given-names></name><name><surname>Ou</surname><given-names>C.</given-names></name><name><surname>He</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Shan</surname><given-names>H.</given-names></name><name><surname>Lei</surname><given-names>C.</given-names></name><name><surname>Hui</surname><given-names>D.S.C.</given-names></name><name><surname>Du</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Zeng</surname><given-names>G.</given-names></name><name><surname>Yuen</surname><given-names>K.-Y.</given-names></name><name><surname>Chen</surname><given-names>R.</given-names></name><name><surname>Tang</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>T.</given-names></name><name><surname>Chen</surname><given-names>P.</given-names></name><name><surname>Xiang</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Liang</surname><given-names>Z.</given-names></name><name><surname>Peng</surname><given-names>Y.</given-names></name><name><surname>Wei</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Peng</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>Zheng</surname><given-names>Z.</given-names></name><name><surname>Qiu</surname><given-names>S.</given-names></name><name><surname>Luo</surname><given-names>J.</given-names></name><name><surname>Ye</surname><given-names>C.</given-names></name><name><surname>Zhu</surname><given-names>S.</given-names></name><name><surname>Zhong</surname><given-names>N.</given-names></name></person-group><article-title>Clinical characteristics of coronavirus disease 2019 in China</article-title><source>N. Engl. J. Med.</source><year>2020</year><pub-id pub-id-type="doi">10.1056/nejmoa2002032</pub-id></element-citation></ref><ref id="bb0315"><label>63</label><element-citation publication-type="journal" id="rf0310"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>N.</given-names></name><name><surname>Zhou</surname><given-names>M.</given-names></name><name><surname>Dong</surname><given-names>X.</given-names></name><name><surname>Qu</surname><given-names>J.</given-names></name><name><surname>Gong</surname><given-names>F.</given-names></name><name><surname>Han</surname><given-names>Y.</given-names></name><name><surname>Qiu</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Wei</surname><given-names>Y.</given-names></name><name><surname>Xia</surname><given-names>J.</given-names></name><name><surname>Yu</surname><given-names>T.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name></person-group><article-title>Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study</article-title><source>Lancet.</source><volume>395</volume><year>2020</year><fpage>507</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30211-7</pub-id><pub-id pub-id-type="pmid">32007143</pub-id></element-citation></ref><ref id="bb0320"><label>64</label><element-citation publication-type="journal" id="rf0315"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Ren</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Fan</surname><given-names>G.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Gu</surname><given-names>X.</given-names></name><name><surname>Cheng</surname><given-names>Z.</given-names></name><name><surname>Yu</surname><given-names>T.</given-names></name><name><surname>Xia</surname><given-names>J.</given-names></name><name><surname>Wei</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>W.</given-names></name><name><surname>Xie</surname><given-names>X.</given-names></name><name><surname>Yin</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>M.</given-names></name><name><surname>Xiao</surname><given-names>Y.</given-names></name><name><surname>Gao</surname><given-names>H.</given-names></name><name><surname>Guo</surname><given-names>L.</given-names></name><name><surname>Xie</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>G.</given-names></name><name><surname>Jiang</surname><given-names>R.</given-names></name><name><surname>Gao</surname><given-names>Z.</given-names></name><name><surname>Jin</surname><given-names>Q.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Cao</surname><given-names>B.</given-names></name></person-group><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title><source>Lancet.</source><volume>395</volume><year>2020</year><fpage>497</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30183-5</pub-id><pub-id pub-id-type="pmid">31986264</pub-id></element-citation></ref><ref id="bb0325"><label>65</label><element-citation publication-type="journal" id="rf0320"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Cai</surname><given-names>Y.</given-names></name><name><surname>Xia</surname><given-names>J.</given-names></name><name><surname>Zhou</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>S.</given-names></name><name><surname>Huang</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Zhou</surname><given-names>X.</given-names></name><name><surname>Du</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Song</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Chao</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Zhou</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>D.</given-names></name><name><surname>Xiong</surname><given-names>W.</given-names></name><name><surname>Xu</surname><given-names>L.</given-names></name><name><surname>Zhou</surname><given-names>F.</given-names></name><name><surname>Jiang</surname><given-names>J.</given-names></name><name><surname>Bai</surname><given-names>C.</given-names></name><name><surname>Zheng</surname><given-names>J.</given-names></name><name><surname>Song</surname><given-names>Y.</given-names></name></person-group><article-title>Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China</article-title><source>JAMA Intern. Med.</source><year>2020</year><pub-id pub-id-type="doi">10.1001/jamainternmed.2020.0994</pub-id></element-citation></ref><ref id="bb0330"><label>66</label><element-citation publication-type="journal" id="rf0325"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name><name><surname>Hu</surname><given-names>C.</given-names></name><name><surname>Zhu</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Xiang</surname><given-names>H.</given-names></name><name><surname>Cheng</surname><given-names>Z.</given-names></name><name><surname>Xiong</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Peng</surname><given-names>Z.</given-names></name></person-group><article-title>Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China</article-title><source>JAMA - J. Am. Med. Assoc.</source><volume>323</volume><year>2020</year><fpage>1061</fpage><lpage>1069</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.1585</pub-id></element-citation></ref><ref id="bb0335"><label>67</label><element-citation publication-type="journal" id="rf0330"><person-group person-group-type="author"><name><surname>Han</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>R.</given-names></name><name><surname>Liu</surname><given-names>F.</given-names></name><name><surname>Wu</surname><given-names>K.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Zhu</surname><given-names>C.</given-names></name></person-group><article-title>Prominent changes in blood coagulation of patients with SARS-CoV-2 infection</article-title><source>Clin. Chem. Lab. Med.</source><volume>0</volume><year>2020</year><pub-id pub-id-type="doi">10.1515/cclm-2020-0188</pub-id></element-citation></ref><ref id="bb0340"><label>68</label><element-citation publication-type="journal" id="rf0335"><person-group person-group-type="author"><name><surname>Spiezia</surname><given-names>L.</given-names></name><name><surname>Boscolo</surname><given-names>A.</given-names></name><name><surname>Poletto</surname><given-names>F.</given-names></name><name><surname>Cerruti</surname><given-names>L.</given-names></name><name><surname>Tiberio</surname><given-names>I.</given-names></name><name><surname>Campello</surname><given-names>E.</given-names></name><name><surname>Navalesi</surname><given-names>P.</given-names></name><name><surname>Simioni</surname><given-names>P.</given-names></name></person-group><article-title>COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure</article-title><source>Thromb. Haemost.</source><year>2020</year><pub-id pub-id-type="doi">10.1055/s-0040-1710018</pub-id></element-citation></ref><ref id="bb0345"><label>69</label><element-citation publication-type="journal" id="rf0340"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>M.</given-names></name><name><surname>Liang</surname><given-names>X.</given-names></name><name><surname>Wei</surname><given-names>Y.</given-names></name></person-group><article-title>Changes in blood coagulation in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis</article-title><source>Br. J. Haematol.</source><year>2020</year><pub-id pub-id-type="doi">10.1111/bjh.16725</pub-id><comment>(bjh.16725)</comment></element-citation></ref><ref id="bb0350"><label>70</label><element-citation publication-type="journal" id="rf0345"><person-group person-group-type="author"><name><surname>Gralinski</surname><given-names>L.E.</given-names></name><name><surname>Sheahan</surname><given-names>T.P.</given-names></name><name><surname>Morrison</surname><given-names>T.E.</given-names></name><name><surname>Menachery</surname><given-names>V.D.</given-names></name><name><surname>Jensen</surname><given-names>K.</given-names></name><name><surname>Leist</surname><given-names>S.R.</given-names></name><name><surname>Whitmore</surname><given-names>A.</given-names></name><name><surname>Heise</surname><given-names>M.T.</given-names></name><name><surname>Baric</surname><given-names>R.S.</given-names></name></person-group><article-title>Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis</article-title><source>MBio.</source><volume>9</volume><year>2018</year><pub-id pub-id-type="doi">10.1128/mBio.01753-18</pub-id></element-citation></ref><ref id="bb0355"><label>71</label><element-citation publication-type="journal" id="rf0350"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>G.</given-names></name><name><surname>Song</surname><given-names>N.</given-names></name><name><surname>Li</surname><given-names>P.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Guo</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Du</surname><given-names>L.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Guo</surname><given-names>R.</given-names></name><name><surname>Sun</surname><given-names>S.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name></person-group><article-title>Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV</article-title><source>Emerg. Microbes Infect.</source><volume>7</volume><year>2018</year><fpage>77</fpage><pub-id pub-id-type="doi">10.1038/s41426-018-0063-8</pub-id><pub-id pub-id-type="pmid">29691378</pub-id></element-citation></ref><ref id="bb0360"><label>72</label><element-citation publication-type="journal" id="rf0355"><person-group person-group-type="author"><name><surname>Magro</surname><given-names>C.</given-names></name><name><surname>Mulvey</surname><given-names>J.J.</given-names></name><name><surname>Berlin</surname><given-names>D.</given-names></name><name><surname>Nuovo</surname><given-names>G.</given-names></name><name><surname>Salvatore</surname><given-names>S.</given-names></name><name><surname>Harp</surname><given-names>J.</given-names></name><name><surname>Baxter-Stoltzfus</surname><given-names>A.</given-names></name><name><surname>Laurence</surname><given-names>J.</given-names></name></person-group><article-title>Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases</article-title><source>Transl. Res.</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.trsl.2020.04.007</pub-id></element-citation></ref><ref id="bb0365"><label>73</label><element-citation publication-type="book" id="rf0360"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>T.</given-names></name><name><surname>Hu</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Zhu</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Dong</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Fu</surname><given-names>Y.</given-names></name><name><surname>Jin</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>K.</given-names></name><name><surname>Zhao</surname><given-names>S.</given-names></name><name><surname>Xiao</surname><given-names>Y.</given-names></name><name><surname>Luo</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>W.</given-names></name><name><surname>Peng</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>P.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Xie</surname><given-names>Y.</given-names></name><name><surname>Song</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Ma</surname><given-names>Q.</given-names></name><name><surname>Bian</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Mao</surname><given-names>Q.</given-names></name><name><surname>Cao</surname><given-names>C.</given-names></name></person-group><chapter-title>Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation</chapter-title><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.03.29.20041962</pub-id></element-citation></ref><ref id="bb0370"><label>74</label><element-citation publication-type="book" id="rf0365"><person-group person-group-type="author"><name><surname>Metthew Lam</surname><given-names>L.</given-names></name><name><surname>Murphy</surname><given-names>S.J.</given-names></name><name><surname>Kuri-Cervantes</surname><given-names>L.</given-names></name><name><surname>Weisman</surname><given-names>A.R.</given-names></name><name><surname>Ittner</surname><given-names>C.A.G.</given-names></name><name><surname>Reilly</surname><given-names>J.P.</given-names></name><name><surname>Pampena</surname><given-names>M. Betina</given-names></name><name><surname>Betts</surname><given-names>M.R.</given-names></name><name><surname>Wherry</surname><given-names>E. John</given-names></name><name><surname>Song</surname><given-names>W.-C.</given-names></name><name><surname>Lambris</surname><given-names>J.D.</given-names></name><name><surname>Cines</surname><given-names>D.B.</given-names></name><name><surname>Meyer</surname><given-names>N.J.</given-names></name><name><surname>Mangalmurti</surname><given-names>N.S.</given-names></name></person-group><chapter-title>Erythrocytes Reveal Complement Activation in Patients With COVID-19</chapter-title><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.05.20.20104398</pub-id></element-citation></ref></ref-list><ack id="ac0005"><sec id="s0075"><title>Acknowledgments</title><p id="p0210">N/A.</p></sec><sec id="s0080"><title>Declaration of competing interest</title><p id="p0215">None.</p></sec><sec id="s0085"><title>Statement</title><p id="p0220">The corresponding author confirms that he had full access to all the data in the study and had final responsibility for the decision to submit for publication.</p></sec></ack></back></article>